Treatment with Lactobacillus delbruckii inhibits hypertrophic scar fibrosis

Author:

Wu Gaofeng1ORCID,Shen Kuo2,Han Fu2,Cheng Jing2,Han Shichao2,Wang Xiaolei2,Xin Keke2,Hu Dahai1

Affiliation:

1. XijingHospital

2. Xijing Hospital

Abstract

Abstract Hypertrophic scar (HS) is a common complication of skin after burn wounds and is a serious fibrosis disease which lack effective treatments. Scholars have suggested that certain probiotics may significantly impact on fibrosis. Hypertrophic scar derived fibroblasts (HFBs) was treated with or without Lactobacillus delbruckii. The fibrosis was determined under in vivo and in vitro conditions. The results showed that L. delbruckii significantly decreased expression of Collagen I, Collagen III and α-SMA in hypertrophic scar derived fibroblasts (HFBs). Masson and Sirius-red staining results indicated that L. delbruckii significantly reduced both Collagen I and Collagen III expression and inhibited scar hyperplasia in rabbit ear model and L. delbruckii inhibited the proliferation of HFBs. To further assess the mechanism of L. delbruckii inhibit hypertrophic scar fibrosis, ribonucleic acid sequencing and iTRAQ technology was used to analysis HFBs treat with or without L. delbruckii. Results revealed that L. delbruckii exert its inhibiting fibrosis effect by targeting multiple pathways at both the proteome and transcriptome levels. L. delbruckii decreased the fibrosis of hypertrophic scar which may provide pharmacological evidence to aid in its clinical application.

Publisher

Research Square Platform LLC

Reference32 articles.

1. The Akt/FoxO/p27(Kip1) axis contributes to the anti-proliferation of pentoxifylline in hypertrophic scars;Yang F;J Cell Mol Med,2019

2. Scarless wound healing: finding the right cells and signals;Leavitt T;Cell Tissue Res,2016

3. Yang, S., Luo, Y. J. & Luo, C. Network Meta-Analysis of Different Clinical Commonly Used Drugs for the Treatment of Hypertrophic Scar and Keloid. Front Med-Lausanne 8, doi:ARTN 69162810.3389/fmed.2021.691628 (2021).

4. Novel targets and therapies for keloid;Naik PP;Clin Exp Dermatol,2021

5. Probiotic Alternative to Chlorhexidine in Periodontal Therapy: Evaluation of Clinical and Microbiological Parameters;Butera A;Microorganisms,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3